KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) EBT (2016 - 2026)

NovoCure's EBT history spans 13 years, with the latest figure at -$69.3 million for Q1 2026.

  • On a quarterly basis, EBT fell 128.61% to -$69.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$175.2 million, a 34.97% decrease, with the full-year FY2025 number at -$136.2 million, down 3.88% from a year prior.
  • EBT hit -$69.3 million in Q1 2026 for NovoCure, down from -$41.0 million in the prior quarter.
  • Over the last five years, EBT for NVCR hit a ceiling of -$2.5 million in Q1 2022 and a floor of -$69.3 million in Q1 2026.
  • Historically, EBT has averaged -$35.9 million across 5 years, with a median of -$32.6 million in 2022.
  • Biggest five-year swings in EBT: tumbled 1931.01% in 2023 and later skyrocketed 57.83% in 2024.
  • Tracing NVCR's EBT over 5 years: stood at -$32.6 million in 2022, then decreased by 18.35% to -$38.5 million in 2023, then crashed by 43.27% to -$55.2 million in 2024, then grew by 25.82% to -$41.0 million in 2025, then crashed by 69.11% to -$69.3 million in 2026.
  • Business Quant data shows EBT for NVCR at -$69.3 million in Q1 2026, -$41.0 million in Q4 2025, and -$30.0 million in Q3 2025.